Literature DB >> 24633526

Rechallenging clozapine after neuroleptic malignant syndrome.

Emaya Anbalagan1, Muaid Ithman, John Lauriello.   

Abstract

Neuroleptic malignant syndrome (NMS) is a potentially fatal manifestation of antipsychotic use associated with symptoms that include mental status changes, muscle rigidity, fever and autonomic dysfunction. An occurrence of NMS with clozapine has been reported in the past but there are very few reports of successfully rechallenging the drug in individuals who have developed the syndrome. This case report discusses one of the few instances in literature where clozapine has been re-administered successfully to a patient without a reoccurrence of NMS. In conclusion, a rechallenge of clozapine after neuroleptic malignant syndrome can be done if care is taken to avoid concurrent use of lithium and other psychotropics, monitoring for NMS symptoms and titrating the dose upward slowly after a reasonable period of time.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633526     DOI: 10.1007/s11126-014-9291-9

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  11 in total

1.  An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge.

Authors:  M G Goates; J I Escobar
Journal:  J Clin Psychopharmacol       Date:  1992-04       Impact factor: 3.153

2.  Apparent neuroleptic malignant syndrome with clozapine and lithium.

Authors:  H G Pope; J O Cole; P T Choras; C E Fulwiler
Journal:  J Nerv Ment Dis       Date:  1986-08       Impact factor: 2.254

3.  Neuroleptic malignant syndrome and clozapine monotherapy.

Authors:  R Chatterton; S Cardy; T M Schramm
Journal:  Aust N Z J Psychiatry       Date:  1996-10       Impact factor: 5.744

Review 4.  When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.

Authors:  Peter Manu; Deepak Sarpal; Owen Muir; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2011-11-22       Impact factor: 4.939

5.  Fluoxetine and neuroleptic malignant syndrome.

Authors:  M Halman; D S Goldbloom
Journal:  Biol Psychiatry       Date:  1990-09-15       Impact factor: 13.382

6.  Neuroleptic malignant syndrome associated with clozapine use.

Authors:  E S Anderson; P S Powers
Journal:  J Clin Psychiatry       Date:  1991-03       Impact factor: 4.384

Review 7.  Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge.

Authors:  T L Huang
Journal:  Chang Gung Med J       Date:  2001-08

8.  The clinical significance of serial creatine phosphokinase estimations in acute ward admissions.

Authors:  K Wilhelm; J Curtis; V Birkett; J Kenney-Herbert
Journal:  Aust N Z J Psychiatry       Date:  1994-09       Impact factor: 5.744

9.  Neuroleptic malignant syndrome associated with clozapine treatment.

Authors:  G Tsai; G Crisostomo; M L Rosenblatt; T A Stern
Journal:  Ann Clin Psychiatry       Date:  1995-06       Impact factor: 1.567

Review 10.  Recurrence of neuroleptic malignant syndrome.

Authors:  V L Susman; G Addonizio
Journal:  J Nerv Ment Dis       Date:  1988-04       Impact factor: 2.254

View more
  2 in total

Review 1.  [Neuroleptic malignant syndrome].

Authors:  R Knorr; J Schöllkopf; E Haen
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

2.  Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association.

Authors:  Siddharth Sarkar; Nitin Gupta
Journal:  BJPsych Bull       Date:  2017-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.